Growth inhibition of combined treatment of cationic liposome/p53 complexes and cisplatin on human carcinoma cells

Abstract

A combination of cationic liposome/green fluorescence protein (GFP)-p53 complexes and a chemotherapeutic drug, cisplatin, was evaluated for therapeutic activity in human carcinoma cells. Cationic liposome/GFP-p53 complexes and cationic liposome/PEI (polyethylenimine) 0.8k/GFP-p53 complexes were synthesized and evaluated in HeLa and in A549 cells for uptake and cytotoxicity, alone and in combination with cisplatin. The particle size of cationic liposome/GFP-p53 complexes and cationic liposome/PEI 0.8K/GFP-p53 complexes was 318 ± 18 to 754 ± 108 nm, and zeta potentials were-15.7±2.8-+27±08 mV. The GFP expression on the delivery by cationic liposome/pEGFP (enhanced green fluorescence protein) complexes and cationic liposome/PEI 0.8K/pEGFP complexes was demonstrated. Treatment of the cells with either cationic liposome/GFP-p53 complexes or cationic liposome/PEI 0.8K/GFP-p53 complexes inhibited the cell growth. On post treatment with cisplatin, the growth inhibition of the complexes was further increased in HeLa cells and significantly increased in A549 cells on the lipid-to-DNA ratio. This study concluded that the sensitivity to the cancer cells to cisplatin was dependent on the cell line and the ratio of cationic liposome and GFP-p53. GFP-p53 expression delivered by cationic liposome/GFP-p53 complexes would be useful to increase the effect of cisplatin on the treatment of cancer cells. © 2020 Weecharangsan and Lee.